by Gary Finnegan: People with terminal cancer often require palliative care in the late stages of their lives. This branch of medicine has long been lauded for the… read more.
by Bruce Sylvester: Investigators from the phase III PALOMA-3 trial report that treatment with the recently FDA-approved drug palbociclib more than doubled the time to cancer recurrence among… read more.
by Bruce Sylvester: Treatment of advanced melanoma with a combination of nivolumab (Opdivo™) and ipilimumab (Yervoy™) or with nivolumab alone increases progression-free survival over ipilimumab monotherapy, researchers reported… read more.
by Bruce Sylvester: Anastrozole is significantly more effective than tamoxifen in preventing cancer recurrence after lumpectomy and radiation therapy in postmenopausal women, age 60 or younger with DCIS… read more.
by Bruce Sylvester: Pembrolizumab (Keytruda®), an anti-PD-1 antibody immunotherapy has shown efficacy in one fourth of patients with recurrent or metastatic head and neck cancer, researchers reported on… read more.
by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.
Results highlight importance of pre-test counselling for at-risk patient populations. Some at-risk patients opted out of comprehensive cancer gene screening when presented with the opportunity to be tested… read more.
by Bruce Sylvester: Patients with metastatic melanoma treated with dual sargramostim/ipilimumab rather than ipilimumab alone have achieved longer overall survival and lower toxicity, but no difference in progression-free… read more.
by Thomas R. Collins: Treating patients with T-cell lymphomas is fraught with challenges, requiring new approaches and sharper diagnosis, said Timothy Illidge, MD, PhD, Professor of Targeted Therapy… read more.
by Esther Drain: A sub-group analysis of the CRYSTAL study. In the CRYSTAL study, adding cetuximab (cet) to first-line chemotherapy (CT) improved clinical outcome in patients (pts) with RAS… read more.
Engagement of patients and understanding of early death in this group by Denys Wheatley. (1) When and why do teenage and young adult oncology patients die early in… read more.
by Denys Wheatley: Chaired by Atsushi Ohtsu and Jean-Yves Douillard, the first speaker Dr Kato (Japan) addressed the issue of the quest for different mutations in the hope… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
